Savara Inc
SVRAUnited States
62 filed reports · 713 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
62 reports · Jun 2011 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 46 | 5,069 | Jun 2011 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 15 | 5,003 | Dec 2011 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2024 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 11, 2026 | 298 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 12, 2026 | 166 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 13, 2026 | 537 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 12, 2025 | 190 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 13, 2025 | 126 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 13, 2025 | 115 | Open |
| FY2024 | 10-K/A | Dec 31, 2024 | Apr 25, 2025 | 1 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 27, 2025 | 319 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 132 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 12, 2024 | 102 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 105 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 7, 2024 | 304 | Open |
Financial data
713 concepts · 10,073 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial704 concepts · 9,949 facts · Dec 1996 to Jun 2026
- Stockholders equity (US GAAP)105 · Dec 1996 to Jun 2026
- Net income loss94 · Dec 1997 to Jun 2026
- Cash and cash equivalents at carrying value83 · Dec 2009 to Jun 2026
- Operating expenses (US GAAP)81 · Jun 2010 to Jun 2026
- Operating income loss81 · Jun 2010 to Jun 2026
- Research and development expense excluding acquired in process cost81 · Jun 2010 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets80 · Sep 2010 to Jun 2026
- Net income loss available to common stockholders basic80 · Jun 2010 to Jun 2026
- Other nonoperating income expense80 · Sep 2010 to Jun 2026
- Share based compensation80 · Sep 2010 to Jun 2026
- Common stock shares issued79 · Dec 2010 to Jun 2026
- Accounts payable current78 · Dec 2010 to Jun 2026
- Accrued liabilities current78 · Dec 2010 to Jun 2026
- Additional paid in capital common stock78 · Dec 2010 to Jun 2026
- Assets78 · Dec 2010 to Jun 2026
- Assets current78 · Dec 2010 to Jun 2026
- Common stock par or stated value per share78 · Dec 2010 to Jun 2026
- Common stock shares authorized78 · Dec 2010 to Jun 2026
- Common stock value78 · Dec 2010 to Jun 2026
- Liabilities and stockholders equity78 · Dec 2010 to Jun 2026
- Liabilities current78 · Dec 2010 to Jun 2026
- Other assets noncurrent78 · Dec 2010 to Jun 2026
- Property plant and equipment net78 · Dec 2010 to Jun 2026
- Accumulated other comprehensive income loss net of tax77 · Dec 2010 to Jun 2026
Product9 concepts · 124 facts · Sep 2017 to Jun 2026
- PARI52 · Dec 2017 to Mar 2025
- Revenue32 · Sep 2018 to Jun 2026
- NTM12 · Dec 2018 to Jun 2020
- Molgradex (aPAP) Japanese Licensee10 · Dec 2018 to Dec 2019
- Molgradex API Manufacturer8 · Sep 2017 to Mar 2019
- Molgradex Japanese Licensee5 · Mar 2019 to Dec 2019
- Apulmiq Licensor3 · Mar 2020 to Sep 2020
- Active Pharmaceutical Ingredients1 · Sep 2017
- Payments for fees1 · Mar 2024
Segments
124 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis7 members · 115 facts
- Nebulizer43 · Sep 2018 to Mar 2025
- Product32 · Sep 2018 to Jun 2026
- Autoimmune Pulmonary Alveolar Proteinosis15 · Dec 2018 to Dec 2019
- Nontuberculous Mycobacterial12 · Dec 2018 to Jun 2020
- Active Pharmaceutical Ingredients6 · Sep 2018 to Mar 2019
- Apulmiq Licensor6 · Mar 2020 to Sep 2020
- Second Source1 · Mar 2024
Product or serviceus-gaap:ProductOrServiceAxis2 members · 9 facts
- Active Pharmaceutical Ingredients7 · Sep 2017 to Mar 2018
- Nebulizer2 · Dec 2017 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.